Vbi Vaccines Stock Working Capital
VBIV Stock | USD 0.60 0.02 3.45% |
VBI Vaccines fundamentals help investors to digest information that contributes to VBI Vaccines' financial success or failures. It also enables traders to predict the movement of VBI Stock. The fundamental analysis module provides a way to measure VBI Vaccines' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to VBI Vaccines stock.
Net Working Capital is likely to climb to about 67.1 M in 2024, despite the fact that Change In Working Capital is likely to grow to (9.4 M). VBI | Working Capital |
VBI Working Capital Analysis
VBI Vaccines' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
2021 | 2022 | 2023 | 2024 (projected) | Total Stockholder Equity | 143.9M | 64.2M | 73.8M | 57.5M | Total Assets | 210.3M | 155.1M | 178.3M | 187.3M |
Working Capital | = | Current Assets | - | Current Liabilities |
Current VBI Vaccines Working Capital | 40.75 M |
Most of VBI Vaccines' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, VBI Vaccines is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
VBI Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for VBI Vaccines is extremely important. It helps to project a fair market value of VBI Stock properly, considering its historical fundamentals such as Working Capital. Since VBI Vaccines' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of VBI Vaccines' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of VBI Vaccines' interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition |
VBI Capital Surpluse
Capital Surpluse |
|
As per the company's disclosures, VBI Vaccines has a Working Capital of 40.75 M. This is 90.43% lower than that of the Biotechnology sector and 92.43% lower than that of the Health Care industry. The working capital for all United States stocks is 97.24% higher than that of the company.
VBI Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VBI Vaccines' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of VBI Vaccines could also be used in its relative valuation, which is a method of valuing VBI Vaccines by comparing valuation metrics of similar companies.VBI Vaccines is currently under evaluation in working capital category among related companies.
VBI Fundamentals
Return On Equity | -2.2 | ||||
Return On Asset | -0.29 | ||||
Operating Margin | (0.98) % | ||||
Current Valuation | 31.14 M | ||||
Shares Outstanding | 23.69 M | ||||
Shares Owned By Insiders | 9.19 % | ||||
Shares Owned By Institutions | 14.15 % | ||||
Number Of Shares Shorted | 302.88 K | ||||
Price To Earning | (3.79) X | ||||
Price To Book | 0.70 X | ||||
Price To Sales | 1.68 X | ||||
Revenue | 8.12 M | ||||
Gross Profit | (10.19 M) | ||||
EBITDA | (62.35 M) | ||||
Net Income | (113.96 M) | ||||
Cash And Equivalents | 82.41 M | ||||
Cash Per Share | 0.32 X | ||||
Total Debt | 52.23 M | ||||
Debt To Equity | 0.32 % | ||||
Current Ratio | 2.29 X | ||||
Book Value Per Share | 0.85 X | ||||
Cash Flow From Operations | (67.87 M) | ||||
Short Ratio | 1.42 X | ||||
Earnings Per Share | (9.79) X | ||||
Target Price | 6.0 | ||||
Number Of Employees | 190 | ||||
Beta | 1.91 | ||||
Market Capitalization | 13.62 M | ||||
Total Asset | 155.09 M | ||||
Retained Earnings | (489.61 M) | ||||
Working Capital | 40.75 M | ||||
Current Asset | 7.89 M | ||||
Current Liabilities | 3.03 M | ||||
Z Score | -5.22 | ||||
Net Asset | 155.09 M |
About VBI Vaccines Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze VBI Vaccines's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VBI Vaccines using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VBI Vaccines based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported | Projected for 2024 | ||
Net Working Capital | 46.9 M | 67.1 M | |
Change In Working Capital | -9.9 M | -9.4 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
GOOG | Alphabet Class C | |
S | SentinelOne |
Check out VBI Vaccines Piotroski F Score and VBI Vaccines Altman Z Score analysis. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for VBI Stock analysis
When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is VBI Vaccines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VBI Vaccines. If investors know VBI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VBI Vaccines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.79) | Revenue Per Share 0.689 | Quarterly Revenue Growth 19.896 | Return On Assets (0.29) | Return On Equity (2.20) |
The market value of VBI Vaccines is measured differently than its book value, which is the value of VBI that is recorded on the company's balance sheet. Investors also form their own opinion of VBI Vaccines' value that differs from its market value or its book value, called intrinsic value, which is VBI Vaccines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VBI Vaccines' market value can be influenced by many factors that don't directly affect VBI Vaccines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VBI Vaccines' value and its price as these two are different measures arrived at by different means. Investors typically determine if VBI Vaccines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VBI Vaccines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.